Professional development Vacancies

Overview of the recommendations adopted by the PRAC committee on signals discussed at the meeting of 23-26 November 2020

14.01.2021 1146 views

medicinal products containing capecitabine – anaphylactic reactions

Having considered the available evidence from EudraVigilance and the literature, as well as the association of medicinal products containing capecitabine with angioedema, the PRAC agreed that registration certificate holders for medicinal products containing capecitabine should, within 2 months, submit variations to update the package insert as indicated below (new text underlined):

  • in the section of the instructions “Adverse reactions” – in “Summary of concomitant adverse reactions reported in patients receiving capecitabine monotherapy” in the tabular list of adverse reactions, under immune system disorders with the frequency “rare”, add angioedema.
Перелік лікарських засобів, що містять capecitabine і дозволені для медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 04.01.2021)

Linkhttps://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-23-26-november-2020-prac-meeting_en.pdf